NOVAVAX INC 8-K

What Happened

• Novavax, Inc. filed a Form 8-K on January 12, 2026 (Item 2.02 and 7.01) announcing it will provide an investor update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and has prepared preliminary financial data for the year ended December 31, 2025.
• The preliminary 2025 financial information is unaudited, prepared by management, and Ernst & Young LLP has not audited, reviewed, compiled, or performed procedures on these amounts. The company cautioned the preliminary figures may change and are not a substitute for GAAP financial statements. The investor presentation is attached as Exhibit 99.1.

Key Details

• Filing date: January 12, 2026; reporting period: year ended December 31, 2025.
• Preliminary financial data is unaudited and may differ materially from the final audited results.
• The 8-K includes forward-looking statements, including projected combined annual research & development and selling, general & administrative (R&D + SG&A) expenses for 2025, 2026, and 2027.
• Novavax will present strategic and business updates at the J.P. Morgan Healthcare Conference; presentation attached as Exhibit 99.1.

Why It Matters

• For investors, this is an early, non‑audited snapshot of Novavax’s 2025 results and guidance on near‑term expense expectations; final audited results could materially differ.
• The investor presentation may provide strategic context (business updates and outlook), but investors should wait for the full audited financial statements and read the company’s risk disclosures before relying on the preliminary figures.